for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dynavax Technologies Corporation

DVAX.O

Latest Trade

9.01USD

Change

0.05(+0.56%)

Volume

4,290,161

Today's Range

8.52

 - 

9.10

52 Week Range

1.80

 - 

12.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.96
Open
9.00
Volume
4,290,161
3M AVG Volume
163.02
Today's High
9.10
Today's Low
8.52
52 Week High
12.44
52 Week Low
1.80
Shares Out (MIL)
101.60
Market Cap (MIL)
823.97
Forward P/E
-12.20
Dividend (Yield %)
--

Next Event

Q2 2020 Dynavax Technologies Corp Earnings Release

Latest Developments

More

Trisalus Life Sciences Acquires Dynavax’S Sd-101 Oncology Program In Purchase Agreement For Up To $250 Mln

Dynavax, Medigen Collaborate To Develop Covid-19 Vaccine Candidate

Dynavax Files For Shelf Of Upto 14.6 Million Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Industry

Biotechnology & Drugs

Contact Info

2100 POWELL STREET, SUITE 900

EMERYVILLE, CA

94608

United States

+1.510.8485100

http://www.dynavax.com/

Executive Leadership

Andrew A. F. Hack

Interim Independent Chairman of the Board

David F. Novack

President, Chief Operating Officer

Ryan Spencer

Chief Executive Officer, Director

Michael S. Ostrach

Chief Financial Officer, Senior Vice President, Chief Business Officer

Robert Janssen

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.790

2018

-2.550

2019

-2.160

2020(E)

-0.775
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.41
Price To Book (MRQ)
60.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1,518.80
LT Debt To Equity (MRQ)
1,518.80
Return on Investment (TTM)
-51.83
Return on Equity (TTM)
-45.16

Latest News

Latest News

BRIEF-Dynavax Tech, Times Pharmacy Announce Partnership To Offer Heplisav-B Hepatitis B Vaccine To Customers Throughout Oahu

* DYNAVAX TECHNOLOGIES CORP - CO, TIMES PHARMACY ANNOUNCE PARTNERSHIP TO OFFER HEPLISAV-B HEPATITIS B VACCINE TO CUSTOMERS THROUGHOUT OAHU Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Dynavax Files For Shelf Of Upto 14.6 Million Shares Of Common Stock

* DYNAVAX FILES FOR SHELF OF UPTO 14.6 MILLION SHARES OF COMMON STOCK, INCLUDING SERIES B CONVERTIBLE PREFERRED STOCK, WARRANTS BY SELLING HOLDERS - FILING Further company coverage:

BRIEF-Dynavax Says First Participants Dosed In Trial For Clover's COVID-19 S-Trimer Vaccine Candidate

* DYNAVAX ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING CLOVER BIOPHARMACEUTICALS’ COVID-19 S-TRIMER VACCINE CANDIDATE WITH CPG 1018 ADJUVANT

China's Clover begins human trials of COVID-19 shot with GSK, Dynavax boosters

A potential coronavirus vaccine being developed by China's Clover Biopharmaceuticals using GlaxoSmithKline's vaccine booster is now in early-stage testing in humans, the companies said on Friday.

BRIEF-Dynavax Completes Enrollment Of Trial Evaluating Heplisav-B

* DYNAVAX COMPLETES ENROLLMENT OF CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

BRIEF-Dynavax Announces Proposed Public Offering Of Common Stock

* DYNAVAX TECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dynavax Says Intend To Provide Update On Early-Stage Collaborations Regarding Potential Development Of COVID-19 Vaccine

* DYNAVAX TECHNOLOGIES - ON MAY 19, INTENDS TO PROVIDE UPDATE ON EARLY-STAGE COLLABORATIONS REGARDING POTENTIAL DEVELOPMENT OF A VACCINE FOR COVID-19

BRIEF-Dynavax Reports Interim Analysis Of Ongoing Clinical Trial Evaluating Heplisav-B In Patients Undergoing Hemodialysis

* DYNAVAX REPORTS INTERIM ANALYSIS OF ONGOING CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

BRIEF-Valneva And Dynavax Announce Collaboration To Advance Vaccine Development For Covid-19

* VALNEVA AND DYNAVAX ANNOUNCE COLLABORATION TO ADVANCE VACCINE DEVELOPMENT FOR COVID-19

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

BRIEF-Dynavax Donates 10,000 Doses Of Heplisav-B Adult Vaccine

* DYNAVAX TECHNOLOGIES CORP - DONATING 10,000 DOSES OF HEPLISAV-B ADULT VACCINE Source text for Eikon: Further company coverage:

BRIEF-Dynavax And CEPI Announce Collaboration To Support Global Effort To Develop A Vaccine For Coronavirus

* DYNAVAX AND CEPI ANNOUNCE COLLABORATION TO SUPPORT GLOBAL EFFORT TO DEVELOP A VACCINE FOR CORONAVIRUS (COVID-19) Source text for Eikon: Further company coverage:

BRIEF-Dynavax And Cepi Announce Collaboration To Develop Vaccine For Coronavirus

* DYNAVAX AND CEPI ANNOUNCE COLLABORATION TO SUPPORT GLOBAL EFFORT TO DEVELOP A VACCINE FOR CORONAVIRUS (COVID-19)

BRIEF-Dynavax And Clover Biopharmaceuticals Announce Research Collaboration To Evaluate Coronavirus Vaccine Candidate With CPG 1018 Adjuvant

* DYNAVAX AND CLOVER BIOPHARMACEUTICALS ANNOUNCE RESEARCH COLLABORATION TO EVALUATE CORONAVIRUS (COVID-19) VACCINE CANDIDATE WITH CPG 1018 ADJUVANT

BRIEF-Dynavax Announces Q4 Loss Per Share Of $0.44

* DYNAVAX ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Dynavax Announces Collaboration With The University Of Queensland And The Coalition For Epidemic Preparedness Focused On The Development Of A Coronavirus Vaccine

* DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF QUEENSLAND AND THE COALITION FOR EPIDEMIC PREPAREDNESS (CEPI) FOCUSED ON THE DEVELOPMENT OF A CORONAVIRUS (COVID-19) VACCINE Source text for Eikon: Further company coverage:

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Dynavax Technologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up